Earnings call transcript Q1 2023

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the InMode First Quarter 2023 Financial Results Conference Call. All participants will be in listen-only mode. [Operator instructions] After today's presentation, there will be an opportunity to ask questions. [Operator instructions] Please note this event is being recorded.

I'd now like to turn the conference over to Miri Segal, CEO of MS-IR. ahead. go Please

Miri Segal

and to operator for us joining Thank first to quarter Welcome InMode’s XXXX today. you, everyone earnings call.

I provided may pertains to Before that outlined in the begin, would call. release remind statement to we also earnings our safe certain harbor information forward-looking on contain call this today's this statements, and like listeners

the If the Investor to you please release, go not have section received Company's of the a copy of website. Relations

results other Changes today. materially to in actual competitive, could business, the made differ and those statements factors by regulatory expressed from cause technological, forward-looking

historical of Our results performance. are indicative not future necessarily

As and such, give assume as law. except assurance statements to accuracy obligation by to them, update the we can no as forward-looking of our required no

to With that, Moshe go Moshe, and I'd ahead. please CEO. like Chairman to over call Mizrahy, pass the

Moshe Mizrahy

And North Dr. Miri. Chief Co-Founder our me Lickerman, Financial Officer; our for Michael and Finance. Officer; joining Shakil Malca, Chief our everyone our and Dr. are Rafael VP to our America; us. of Lakhani, today Spero in you, Theodorou, With Chief Kreindel, Medical Technology Yair Officer; Thank President

we all Following remarks, your will prepared be answer available question. our to

disrupt small with and the that can moment close of ago with consumable first We the company of expertise increase aesthetic of technology, started $X.X like take go over the a RF treatment quarter, our detail I reported XXXX. more gap. help the and in shortly. knowledge an the of compared industry, to would investment to to Sales XX-years million to and recognize revenue first XX.X%, grow the continued an Shakil will $XXX.X the bipolar and that just from in quarter service quarter first industry this of that and in we idea we

been accomplishing lasting patient have and this We results. remarkable providing by

plastic leading have approved FDA technology. closely our that are working endorsed safe with surgeon We

the technology global aesthetic in across and countries with the innovative wellness that patented can XX,XXX provider is of seven XX over and system installed over States family leading we an Today, operating platforms and solution say globally. base of United in XX InMode product minimal invasive X,XXX

to without we start proud of employees. recognize and to results we to this consistent the are commitment like We And XX-years a I their anniversary work them would care. dedication thank the announced and not the solid our take hard opportunity would strong this reach year, for as to

market. platforms months. launch successfully Envision to Canada. in we targeted Envision year, technology Last innovative U.S. platforms optometrist has introduced in And coming the expect these the for ophthalmology in an the we and

generation forward platform all of mentioned quarter, and updating is Evoke, next free year we As in treatment our to for launch we hands the this on you second-half last face to look planned this the progress.

turn to Shakil, the like would North Shakil, President call our in please. America. over I Now, to

Shakil Lakhani

joining everyone us. and Moshe for Thanks,

growth a report are XX% from This Revenue to happy positive momentum. continued strong consumable with and sell quarter used signifying are we is We grew sales. nearly consumables from demand significant coming indication year-over-year. first the strong frequently platforms and that more being a service

strong ambassadors, to positive A and awareness market benefit patient brand Morpheus from platform continues traction our results. Our gain and

for team expand to begun our we women's platform. Envision for expect Envision hire our wellness in focused sales of As future. reps into ophthalmology, and this we'll market and wellness establish for markets with market as strategy health continue to to Moshe the such We've dedicated mentioned, a new sales optometry areas gradually and

to team like I'd thank their American hard for North Lastly, our work. continued entire

in the Yair Yair? financial I'll now a more results for over of the hand review call detail. to

Yair Malca

is XX.X% past the Thanks, quarter year-over-year XXXX, on of everyone. the $XXX.X gross Shakil, on XX% first Traditionally, in a for representing us. a generated joining you revenue, with in basis. of GAAP quarter first a the based and Starting increase Thank margin hello total slowest InMode with quarter year. seasonality, million our

XXXX year. expect in a to last We to way similar behave

to establish later more XXX compared of with or And growth, outside XX% our sales of over XX hit in U.S. a a XX team additional support million subsidiary total new now in in operations to year. Europe this $XX.X last worldwide. see are at regions To sales quarter record for one or accounted Europe countries, and with and the distributors least First QX we planning XX% QX. coming different reps direct sales in than We in of over growth InMode sales, operates Asia of from year. of

projections. the in direct-to-consumer for advertising expenses first campaigns addition $XX.X million business Capital to new last million increase $XX.X million, the equipment year. attributed period remaining to year-over-year. consumer in events the company's compared investment the XX% as expenses in the same is operating revenues of a representatives, in XX%. quarter total accounted the to while marketing to revenue, This $XX.X increase first quarter, hosting well Sales service in gross quarter sales first increased the GAAP of as and support in-person represented XX% were and

accounted XXXX. of compared Share-based basis, $X.X representing an a a of in in quarter On compensation to for million first non-GAAP total of XXXX, $XX.X the million expenses the were compared same operating million XX% a the the million XXXX, first increase in to $XX increase. in $X.X quarter quarter, quarter of

operating of first in XX%, the of XX% was XXXX. quarter quarter compared XX%, to XXXX. in the for was the QX decrease for XXXX slight margin Non-GAAP a operating of first from margin operating XX% of margin GAAP first an quarter

this Once per compared again, to share quarter ended we the diluted per compared XXXX. of with to share quarter diluted XXXX. strong first earnings diluted a $X.XX, quarter for GAAP $X.XX the were in per share share in sheet. $X.XX, $X.XX the first were diluted Non-GAAP per of quarter balance for earnings QX

and XXXX, cash cash million. deposits XX, March of securities As of the had $XXX.X and equivalents, marketable company

one-time This million, operating of tax generated a million InMode from activities. quarter, $XX $XX.X excluding payment

between for Non-GAAP income XXXX. reiterate Revenues $X.XX. Before Non-GAAP million. XX% diluted share guidance $XXX to margin to between Moshe between our I'd I million, $XXX and turn XX%. operations the and call questions, million like $XXX and to between your million per from $X.XX back non-GAAP gross $XXX earnings take to

now to will the Moshe. over back turn call I

Moshe Mizrahy

we're Thank you, Shakil. Thank ready Yair. for Q&A. you, Operator,

Operator

Thank you.

session. We begin Please the Sarcone will question-and-answer Our from [Operator comes Michael Instructions] ahead. go Jefferies. with first now question

Michael Sarcone

Thanks this for morning. Mike and on good morning. Matt This is

question just on guidance. the So first

You U.S. and some of got really talk assumptions you strong guidance Evoke the nearly how to you had the was there? in just first start year. a in the I the next-gen the that year, comp know and Can about soon Envision in the key about quarter, think and of XH. launching XX% toughest you growth on the

And key guide the it as fair to guide. is some So again, just characterize conservative? assumptions around

Moshe Mizrahy

as claim, would to say, I we Yes. with be guidance. always we try very conservative

to better we Although keep little QX a bit of how the did the guidance end to XXXX, the until QX will see we consensus decided QX on be. than

As business. you know in there is this some seasonality

the is one, of we second stronger be above must then that the -- the quarter. the than first the slowest increasing successfully The quarter will consider the we end estimate the of consensus and much guidance. analysts, second quarter first If quarter with expectation the will

far another see to But estimate. to $XXX will with did better million, more it wait stay compared on conservative this with felt in we the better rate, consensus world, We will what and at and slowdown, $XXX as I will of first be the end increase increase QX. in the quarter be guidance mean, guidance like to million then situation the time $XXX and recession, and million, rest we quarter, much feel U.S. the interest of the as some the

Michael Sarcone

ability your sense. Okay. seeing customers’ are in any you changes makes Thanks, then, to Moshe, And the system? that finance

Moshe Mizrahy

we No, We don't. don't.

United Shakil elaborate have finance want Although the bank last, will it's we in bit I little few on in say something Europe, States, on agreement signed Europe the will easier to the us that. years, that three in helping system. in finance Europe, an for didn't But In we customers and a the customers taking Shakil, that longer, you do words for say, U.S. to would to is example, it that? especially in make with which the

Shakil Lakhani

sure. Yes,

So not that much like Moshe too we're end. said, seeing on

of that used it so at forth. right a to, taking just haven't factor. are kind as so We longer bit and than But a we now, risks little seen we're prohibitive looking seeing on

Michael Sarcone

just you little that's when the And of selling say a cycle? it. bit longer, Got kind

Shakil Lakhani

a yes, who say, even it's wouldn't just little money just requiring ensure a different necessarily buyer degree again well, -- not with the and they're close like their just documents to from -- just what the but to. I selling XXXX-XXXX, it's to that, pickier just happened not cycle, that being in given It's they’ve they're of banks -- basically, back to

to the they So that they ensure just information. appropriate want get

to So, be it. now with proved amount further they documentation with along x you'd able dollars to just application, credit a need get of some provide might previously

XX the to XX hours add it So might process. to

Michael Sarcone

the Is Got do and Interesting to for press net liposuction It one loose expecting? the drugs, you demand it. demand one kind of questions, to more weight I'll procedures the there whether you. was of And lower InMode drugs. influx expect be in when in you're patients. you what's loss that in, any release there an the about loss factor sneak just of my impact offset there. that skin Thank impact for like see going seeing just you're of on popular weight disclosure

Moshe Mizrahy

Spero, answer could please that? you

Spero Theodorou

when we're to in helps question. the Sure. the actually on is come they it's to -- of right? that. us able first Look, be loose weight, So the great tightening already they've patients to the have skin, lost all, contrary, That's company, skin loss a weight because, us the tie

actually them can it still aesthetic if or of what areas that limits fat some they number liposuction, skin, So in loose fat with you does, have of patients But So removed. need right? increases that the areas, it result. kind it you of the have do pockets

tightening So of adding we market. increases capabilities size that addition to the a liposuction the procedure have in

they at to our of this the that amount loss end we What holy to the ability dealing patients cool I the doctors a taken surgery always right? since surgeons Ozempic large tighten the of of a And like weight the done positioned marketing clinics and perhaps, this That's and plastic plastic lot on loss, if and without awareness. drugs increased like day, it's of up remind use a seen these with though this skin and patients depending influx are weight that name, but has we across are our over of perfectly just I'll scars. even skin. board end thing they have advantage take of the have mean, wildfire. excision are with needing grail loose procedure space, deal is is you might

So answer that net, net your question? Did benefit.

Michael Sarcone

Very thank does. you. helpful, It

Spero Theodorou

You're welcome.

Operator

Matt go Please Our comes with Miksic ahead. Barclays. next from question

Unidentified Analyst

specific any Hi, this fair the on see guess, to is just to the is concerns for taking and that, rest to I [Sarah] it (ph) question. general related it our Thanks year of guide, conservatism? on for you say clarify Matt. just the don't

Moshe Mizrahy

I see didn't understand market? the we in question. any Do concern if ask, you the

Unidentified Analyst

answer Yes, -- wanted say just don't specific to earlier, is based your concerns clarify, just it's just general into fair I guidance? to it the see conservatism you’ve on or any that provided current we and

Moshe Mizrahy

we the slowdown, less just hundred. is because our it system potential any on we than the market said the mean, embryonic that we is now of maybe very believe sign signs I technology very operate, today Well, few have the recession any clear, don't we is But I in and of installed stage. XX,XXX see market different.

because only want doing only RF of reshaping, body to with them and they aesthetic do need if account, they face do if do they using into take need the treatment future will you -- others, laser will and all topical who us. they laser are in and bipolar medical If doctors

see don't slowdown. we So any

than have in we say quarter I that the quarter contrary, this of the usually the to fourth quarter sell one. more the is XXXX, On fourth strongest and disposable

before any So wait will we is change guidance raised. if guidance will to the a see gave quarter change. on then because guidance why the the look second reason did quarter We we we quarter, just everything expectation and we slowdown. don't according the to ago, wanted be not The another our

Unidentified Analyst

this has how Understood, then the to that’s on a you right is if still just gears think And and guess, shifting to been XXXX do in Empower, XX% tracking this expect that or in growth acceleration about helpful. I curious bit year. way more

Moshe Mizrahy

quarter, give the sold quarter we Empower XXXX. guidance of quarter, Well, than we first first but more any sold tell that can this on didn't in the you we I

Unidentified Analyst

great. Okay, you. Thank

Operator

comes Your question Please with go UBS. Danielle ahead. from next Antalffy

Danielle Antalffy

the taking everyone. morning, much good Hey, Thanks for so question.

Just allocation. a capital question, Moshe, on

happen about to talked M&A thinking guys sometime for You about potential there think capital year? this on Any deal allocation have to in here. the how a how updates and past potential about you're

Moshe Mizrahy

Yes, say. would $XX,XXX are one. question, the that's Well, than we exploring I opportunities, more

a thing are very diligence, structure the et will money One difficult And check I to some profitability same we due the that InMode. spend to to cetera. -- find with -- of them want even same with say, to be company of

any not easy acquire the dilute It So structure will we It's accretive not company the InMode. not and shareholders. easy. profitability should And of dilutive. not should because that be it's of

very that special the M&A. careful that we're looking companies to and the doing only I attention or for that cannot we're The today. we're like in announce possibility we're spend we say can I do would So analysis management we anything acquisition. exploring a thing on that time, money, on

Danielle Antalffy

on Okay, a just it. That's got indication question expansion. helpful. And then

progress for looking incontinence, making to well, cetera, doing as Thanks any obviously et next much. updates InMode is Empower So measure that, we stress, about against there? think be urinary or steps so beyond -- should we

Moshe Mizrahy

whom? Against think don't against any... we InMode what? have I

Danielle Antalffy

any just measure no, against those in be indications looking progress to whether No, we no, getting like we're for markets. milestones those should launching anything,

Moshe Mizrahy

I quarter we're happy that this today. not believe we'll we changing be last guidance expect than XX% said on to and year, Empower ago more a do

Danielle Antalffy

Thanks. Okay.

Operator

Your go Please ahead. Baird. next Dane Reinhardt with from question comes

Dane Reinhardt

morning, guys. questions. the good Hey, for Thanks

can of, kind any wondering the U.S. on color, Just XX%. more you up placements just maybe if give being

that two anything of to I know what other think know U.S. else What a little kind I Evoke for lighter be those later launching, you and have and So kind investors I was there expecting? plays to have factor, than of kind we later Envision definitely this this there contributes a expect both year? placements is seasonality been we bit impacting? year. able of, might some And

Moshe Mizrahy

Shakil, you on elaborate please could that?

Shakil Lakhani

still or placements path place, changing you too not in we're revenue, placements on. model see amount what don't many far we affecting pretty but to things of have Sure. factors I'm Yes, significant as the at a again, as looking it growth go, down now when And if had growth. comes economic guys sure we you're right that

course, really, number, ready, nice of market I think building it us. plans out some and mentioned we obviously, anticipate force a but the things about getting we're going further growth, pretty have Can't substantial in out sales kind be do a little growth. Of we a and we're there the dedicated to, as that. to feeling you for to excited script is extremely runway and in Envision see give We

Dane Reinhardt

Thank Okay. you.

Shakil Lakhani

mainly QX slowest in in I think it the tends and especially due year to seasonality, was we mainly be seasonality. this It the to was see effect the U.S.

I So, to add. would that's something like that

Moshe Mizrahy

medical or It's not the think something aesthetic new, can I so that it's category InMode or that. industry whatever, been change like don't in that

Spero Theodorou

Spero, I think here. --

advance. picture months for demand in what's there the two, the see to outline ground saying, booked, think of booked Most and between are what I We what still we're doctors. a and that on demand physicians very seeing three for is high. important is macro solidly patients discrepancy the are slowdown, the people any don't is

is we we're we're all seeing if what seeing about, from talked that something So not the that's and sort it concerned offices of there people to. are

you if helps that at So, all.

Dane Reinhardt

Okay, I then here kind And other two we've MorpheusX new in yes. you. some micro burst and know more needling modes, just the on competition been launches. some the competitive over of past seeing year with or Thank XD

competition? MorpheusX of, little designer just new, us a on differentiating you you maybe how help believe options can kind these So bipolar it's bit more give color and versus

Moshe Mizrahy

Okay.

of from that, the by deep the energy the needling all others doing a to a only which so is much protected I micro the needling. brand RF, what call deliver the create Unlike all Morpheus RF only and the level better. say make is The basically name basically the well the delivering of all epidermis, to that's tip of which -- on fractional want MorpheusX, because First, RF, it's pin, on the comparison technology bipolar energy we as RF which market, other fractional skin. our device, fractional the the micro something while about the than total results the

pin time any basically is the same for all second it's equal Morpheus advantage it pins consuming and in eliminate make pins have the time regarding and spot doctor because and of uneven -- energy minor make use the the technology. which XD, Now electrode of the bipolar of give for in distribution four it's treatment. tips something XX to that return develop kind treatment, the the the be but to but it. the distribution the wanted saving will skin, some between on It's size time that And overall, body just In we therefore we -- a the is -- treatment, and sure change, we developed treatment. XD larger we body electrode

Dane Reinhardt

can Okay, have given last an And thank you. consumables just every kind one. sneak then absolute you And if number I of one quarter of I sold. think

last and quarters quarter to first prior X,XXX that. I just wondering for X,XXX the think I quarter. update could was it that you was if like the two

Moshe Mizrahy

XXX,XXX We pieces. did

Dane Reinhardt

questions. Okay, thank the you. Appreciate

Operator

Matson with Our Needham next from question Please ahead. Mike & Company. comes go

Mike Matson

taking Yes, thanks questions. my for

pattern starting Just you're And launched been that us the I give on with you markets wondering guess kind where could of, an then launching similar Empower, has update at, product you in? U.S., if launch it which outside I and guess, to going first mean the when the is question of U.S.? product, be in that for that as kind follow, U.S., Empower will a I similar outside Envision, do

Moshe Mizrahy

approved countries. countries big Brazil, in other only working The Empower not certain in It's right a not in America. is Okay. now Latin which Argentina, Mexico yet we're in in approved is in now and and market,

and the the to MDR, We individual MDD have In several changing they call already from regulatory most it's Europe, have platforms again explain and some go countries, with system right in is it's complicated, Europe, fact introducing it. to But re-approval in because in in to in we the to process that we're body. I due the these of and regulation and what will countries not Europe, deal doing it we're to certain countries, do in but difference, now. approved try

U.S. from be by luminary it This that bring countries, U.K. some the in quarter Spain, would introduced France. will main doctor and three

Japan Following one is that not yet. is Asia, a regulation, introduce in Italy it's in cleared we're time. a only we in have Italy. the from system that we it's the take process, Australia. regulatory, Also now. in will India China, don't Korea which clearance the In and we system country, but special clear yet the starting In

So Canada, the cleared, as situation outside there. that's you the the U.S. U.S., already selling In it's know, in was

As Envision, as outside know, Canada the as soft far starting you U.S., not started did U.S., we before part of launch yet. in the and the other we have world, we the in a

Mike Matson

BodyTite, you. And within mean, break category, kind the you are on quite lines, Thank is product MorpheusX the I bit they there. or all that have MorpheusX, be other it. MorpheusX, know of, primary mean, I the a equally or don't is Is growth -- buzz out, probably but and contributing everything? of got social Okay, kind sales of -- is invasive FaceTite, just generating then minimally places. I by in things does other to seem media some the detailed you to driver there just

Moshe Mizrahy

not it's Well, star, only MorpheusX is one. but the the

sell all the We Optimas the with other handpieces. continue to

FaceTite of more different in in that go everything we're can that We Europe. the is to handpiece in minimal not in Yes, the doing incorporate is developing mini the a platforms, make with the BodyTite, good and try basically well to which We're Asia have attractive. we Morpheus in platform, a body results Morpheus type order affects. technology, platforms invasive very with affects, Morpheus

body In Forma, plus. and Forma, treatment addition, affects we're and mini combination Morpheus and body developing affects of

-- So and combining with by portfolio we growing in by synergizing technologies a the the between market in the handpieces. to continue and growing develop existing

Mike Matson

Okay.

Spero Theodorou

teaching aesthetics. what just in in to Mike, office, company, business, do we're They sort and the important these Spero, right? this looked doctors into at incontinence, used we're When in technologies have a our give an which have already narrative not is is And they they're go going this And how with Primarily -- ophthalmology we we really urinary business, audience, captive something Empower, we of going that's then stress and went we're aesthetics. increasing you by gynecology OBGYN other is a is charging right? we their our to with looked little all color. is, aesthetics know, to we look for. at why have come to they teach the patients we this them TAM,

our United on sold platform. at six tip So or that saw the across was for intravascular used North we Morpheus the for that in top our is States, board and the every there theory. America Morpheus reason accounts Morpheus Empower We looked tips tips used aesthetics in

across looked narrative X.X about every population So we with, that and with the we that how something they intravascular of the sort of tip, Morpheus tip go Morpheus being that, have ones they're for we Morpheus of accounts, and our and tips all proves that. we cosmetic just and body. board, used so the show rest okay, have the comfortable justifies existing sort Then yes, that saw, the we in patient saw

So is that let's our we sense? rising we color playing same that narrative doing aesthetics like said, showed technology company on the That is adoption Mike? and are make the actually through are and an Your Morpheus with us fact a consumables Moshe but plan and the forget little Envision. not

Mike Matson

guess to in on Yes, it of from multiple does. Got terms platforms capabilities, the little platform point, I I actually it's growth your of guess, the at sales. because separate so you. good it's mean, least them, And a it. hard driving what's are I Thank a terms

Spero Theodorou

No problem.

Operator

Rose Kyle ahead. Please with comes go question Canaccord. next Our

Kyle Rose

loss in given to you there. more coming weight that body expect that some you in roll that, expect in products I Morpheus there? a to about but Great, the hands-free, for utilization or BodyTite should commentary it's do new invasive, -- see around have know ask, are -- of minimally drugs patients might wanted of commentary. drive we more all guess going just bit thank I you the I to the just little up the

Shakil Lakhani

Kyle. Hey,

be mix it's to to -- it's be a frankly. going think I actually both I of think going

plastic being able tighten the Spero As of is to mentioned earlier, grail holy surgery skin.

able our is that things Our to looking goal the treat. they're actually surgeon in or help order be physician those provide job for to to tools appropriate to and treat each here

with still So to have patients excisional some they're We're -- there's grade, loss some to away if some said not ways be they that this massive but going going have we well, laxity and BodyTite, the they make that each it's whether trying if FaceTite tools that again, Is sense, actually with Kyle? an or have when -- that so need it's procedure. even need optimize surgeon pick Spero weight provide or that take our there our MorpheusX, and from to as to can get outcomes. in provider, handsfree job to one with use they to or basically the patient for these can choose appropriate technology what of appropriate

Kyle Rose

status call and you've into Yes, helpful. the, commercial what of you teams as go or some those about place some on and then your sales course markets, out the over the about how year on additional those think guidance? had them, relative two, operating guess investments And One, the should wellness guess, And expense the we I some there. -- of taking then I initiatives? to is talked we'll I commentary you've building think it's non-core potentially

Shakil Lakhani

Sure.

mentioned. I from in we're standpoint, of So a as distribution in actually hiring of terms the -- already process

the them And for some InMode made looking way. we’ll quarters. the next from train, several some obviously we're and outside few competitors, hires, that recent to that So, from materialize we've bring over

you've like out the We Again, know, following right as to things like We start. been gate. us you for don't quite to slow while. a Kyle, rushing and do steady

where want of do to a the line way the at bottom we for it sense it's do to line. and sense to company, We it in makes contribute for the to top to So the want day, right. going make it reps, and end

expanding that's it So what anything way. I terms look do distribution major from any terms of in from that in we going already major at to that of lead extraordinary standpoint, costs. don't anything see we -- to

Kyle Rose

Okay. the team. And question, commercial core we'll in it, is just core last the, then I'll the on the business, ask call

little there You've walk there -- the to through maybe, just there? on, got kind taker bit commercial going any talent thoughts in a the a your out or market. R&D drama opportunity of, share off via on And is that some commercial talent being a competitor of us peel of

Shakil Lakhani

as a them secret. leave we'll guess we’re… No, so I Sure.

Spero Theodorou

Why Kyle? that think is, do you

Kyle Rose

exactly. Yes,

Shakil Lakhani

And in right. chaos this we is opportunity, know

So picky we're, with people the that again, wanted and to we way going on. selective on be very that business. again business doing that to bring people to we the bring we're to used we're But do also able are

bring on in again of just maybe now, the going it. help So only InMode we're things only we're right going will and and them we're them absolutely no take hunt is kind because best way. and be, XX% there X% learn to question develop might best about again, over do to but we And to that to exposed the of the

standpoint, minutes super to right major. it's better were the it's are do right something to so But extremely we for way course, probably with probably them and something want to from bring people not going to say able them way. a XX to forth. follow people the opportunity, we're about we're imagine or and we we're likelihood I provide looking in business InMode a to of be again again, the so obviously just able wouldn't -- it's good So on -- XX it that looking you with but could Kyle, leave If minutes, not, on and

Kyle Rose

taking questions. for you Thank Great. the

Shakil Lakhani

course. Of

Operator

question-and-answer closing back to This remarks. session. would concludes turn like conference over our the for any I to Mizrahy Moshe

Moshe Mizrahy

time. will everybody us that us. and sure ask that next for Thanks you I'm your time everybody all. you joining to I I you quarter. question want will happy. operator. today. Thank And all the you you, us See for Thank thank for be thank join next

Operator

attending conference Thank presentation. has The today's you now for concluded.

You disconnect. may now

InMode (INMD) 2 May 232023 Q1 Earnings call transcript